{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055644","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.953860+00:00","generated_at":"2026-06-02T12:06:27.235388+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Erasca Q1 net loss $35.0M ($0.23/shr); cash $297.7M; naporafenib data shows 13-14 mo median OS","bullets":["Net loss $35.0M vs $33.2M YoY; EPS $(0.23) vs $(0.22).","Cash, equivalents & marketable securities $297.7M as of March 31, 2024.","Pooled analysis of naporafenib + trametinib shows median OS 13.0-14.1 months in NRASm melanoma.","Closed oversubscribed $45M private placement in April 2024, extending cash runway into H2 2026.","Upcoming milestones: Phase 3 SEACRAFT-2 initiation Q2 2024; multiple data readouts in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055644","json":"https://secwatch.observer/filing/0000950170-24-055644.json","markdown":"https://secwatch.observer/filing/0000950170-24-055644.md","text":"https://secwatch.observer/filing/0000950170-24-055644.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000095017024055644/0000950170-24-055644-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000095017024055644/eras-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T12:06:27.235388+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"069c297951a2c01baaf416d989e17461fcb95937","claim":"Erasca, Inc. reported the fiscal quarter ended March 31, 2024 results: net income $35.0 million, EPS $(0.23) per basic and diluted share.","evidence_excerpt":"Net loss was $35.0 million, or $(0.23) per basic and diluted share, for the quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761918/000095017024055644/0000950170-24-055644-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended March 31, 2024"},{"label":"Net income","value":"$35.0 million"},{"label":"EPS","value":"$(0.23) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}